Loading
A phase 2 trial of Cinacalcet in Prostate cancer, run by Wake Forest University Health Sciences, completed.
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer is a phase 2 interventional study registered as NCT01054079 by Wake Forest University Health Sciences, with 20 participants recorded, started 2011-09 and reaching its primary completion in 2014-08. Interventions recorded: laboratory biomarker analysis, quality-of-life assessment, questionnaire administration, cinacalcet hydrochloride. Conditions recorded: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer.
Linked to the drug Cinacalcet because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
20 enrolled.
IQR -0.01 to 0.17; Figures from the ClinicalTrials.gov results section (first posted 2015-10-29), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Rate of Rise of Serum PSAprimary | Treatment (Cinacalcet Hydrochloride) | 10 | 0.0825 nanograms per milliliter | - | - | link |
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.